Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis

IMPORTANCE: Programmed cell death (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors have been increasingly used in cancer therapy. Understanding the treatment-related adverse events of these drugs is critical for clinical practice. OBJECTIVE: To evaluate the incidences of treatment-relate...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:JAMA Oncol
Autores principales: Wang, Yucai, Zhou, Shouhao, Yang, Fang, Qi, Xinyue, Wang, Xin, Guan, Xiaoxiang, Shen, Chan, Duma, Narjust, Vera Aguilera, Jesus, Chintakuntlawar, Ashish, Price, Katharine A., Molina, Julian R., Pagliaro, Lance C., Halfdanarson, Thorvardur R., Grothey, Axel, Markovic, Svetomir N., Nowakowski, Grzegorz S., Ansell, Stephen M., Wang, Michael L.
Formato: Artigo
Lenguaje:Inglês
Publicado: American Medical Association 2019
Materias:
Original Investigation
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6487913/
https://ncbi.nlm.nih.gov/pubmed/31021376
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2019.0393
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares